RxDoctor Payments DataLook up a doctor →

Edward Steinmann

Chiropractor · Des Moines, IANPI 1528050622

Payments from drug & device makers

$8,706in general payments, 2019–2025

Across 564 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boehringer Ingelheim$727
  • AstraZeneca$590
  • Pfizer$492
  • Novo Nordisk$486
  • Amgen$442
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,55798%
  • Education$1502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,706 in reported general payments places this provider in the 95th percentile of 51 chiropractor providers in Iowa.

See all chiropractor providers in Iowa

Medicare billing

Part B allowed, 2024
$31,456
Medicare patients
97
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide40$37,812
OzempicSemaglutide29$36,586
JardianceEmpagliflozin35$30,972
MounjaroTirzepatide17$21,804
UbrelvyUbrogepant16$20,790
FarxigaDapagliflozin Propanediol26$18,956
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$14,364
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$13,727
Tresiba Flextouch U-200Insulin Degludec20$12,814
Humalog Kwikpen U-200Insulin Lispro11$9,677
MyrbetriqMirabegron15$8,569
EliquisApixaban14$8,147
TradjentaLinagliptin12$6,695
Arnuity ElliptaFluticasone Furoate19$3,892
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$341$59,61757 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$727$52,03169 claims
Novo NordiskOzempic$486$36,58629 claims
AbbVieUbrelvy$2,261$20,79016 claims
AstraZenecaFarxiga$590$18,95626 claims
Astellas Pharma US IncMyrbetriq$138$8,56915 claims
PfizerEliquis$492$8,14714 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$240$58513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 chiropractor providers in Iowa.

Other chiropractor in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →